Drug intelligence / Profile preview

AMG 701 + pomalidomide + dexamethasone

Development stage: Unknown
Lead developer: Amgen
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous, Oral

Overview

AMG 701 + pomalidomide + dexamethasone is an investigational three-drug combination for the treatment of relapsed or refractory multiple myeloma. AMG 701 is a half-life extended bispecific T-cell engager (BiTE) antibody that targets B-cell maturation antigen (BCMA) on myeloma cells and CD3 on T cells, promoting T-cell-mediated cytotoxicity against the cancer. Pomalidomide is an oral immunomodulatory agent that enhances immune cell activation, inhibits angiogenesis, and induces apoptosis in multiple myeloma cells. Dexamethasone is a synthetic glucocorticoid corticosteroid that suppresses inflammation and immune responses. The combination is being evaluated in phase 1/2 clinical trials for relapsed/refractory multiple myeloma and is designed to leverage synergistic anti-myeloma effects, particularly in patients who have received multiple prior therapies[1][2][4][6].

Other names: pomalidomide + dexamethasone (PomDex)AMG 701-PAMG701-PAMG-701-PAMG 701 + PAMG 701 + pomalidomideAMG 701 + pomalidomide + dexamethasone

Targets

GR (Glucocorticoid receptor)CRBN (Cereblon)BCMA (B-cell maturation antigen)CD3 (T-cell surface glycoprotein CD3)

Beyond the preview

Go deeper on AMG 701 + pomalidomide + dexamethasone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AMG 701 + pomalidomide + dexamethasone.

Explore the full profile